CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.
You may also be interested in...
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.
Sanofi’s Zimulti Goes To Advisory Committee
FDA’s Endocrinologic & Metabolic Drugs Advisory Committee will review the obesity agent, formerly known as Acomplia, June 13.